Incyte (INCY) Change in Accured Expenses (2010 - 2026)
Incyte (INCY) reported Change in Accured Expenses of -$84.7 million for Q1 2026, down 213.21% on a YoY basis from $74.8 million in Q1 2025, and down 161.15% quarter-over-quarter from $138.5 million in Q4 2025.
Incyte (INCY) Change in Accured Expenses (2010 - 2026) Analysis & Trends
Incyte has reported Change in Accured Expenses for 17 years, with the latest figure at -$84.7 million in Q1 2026.
- For the quarter ending Q1 2026, Change in Accured Expenses fell 213.21% year-over-year to -$84.7 million; the trailing twelve-month figure through Mar 2026 stood at -$307.8 million (down 223.94% YoY), and the FY2025 full-year result was -$148.2 million, down 153.13% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at -$84.7 million, down from $138.5 million in the prior quarter.
- The five-year high for Change in Accured Expenses was $138.5 million in Q4 2025, with the low at -$476.7 million in Q2 2025.
- Historically, Change in Accured Expenses has averaged $29.2 million across 5 years, with a median of $71.9 million in 2023.
- Annual changes were most pronounced in 2022 — Change in Accured Expenses surged 2430.46% — and 2025, when it plunged 510.9%.
- Incyte's Change in Accured Expenses stood at $47.8 million in 2022, then jumped by 143.08% to $116.2 million in 2023, then gained by 11.66% to $129.8 million in 2024, then rose by 6.76% to $138.5 million in 2025, then slumped by 161.15% to -$84.7 million in 2026.
- The last three Change in Accured Expenses figures came in at -$84.7 million (Q1 2026), $138.5 million (Q4 2025), and $115.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 931,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 70.50 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Incyte | 19.62 Bn | 15.60 Bn | 1.17 Bn | -84.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -84.73 Mn |
| Mar 31, 2026 | -84.73 Mn |
| Dec 31, 2025 | 138.55 Mn |
| Dec 31, 2025 | 138.55 Mn |
| Sep 30, 2025 | 115.14 Mn |
| Sep 30, 2025 | 115.14 Mn |
| Jun 30, 2025 | -476.73 Mn |
| Jun 30, 2025 | -476.73 Mn |
| Mar 31, 2025 | 74.84 Mn |
| Mar 31, 2025 | 74.84 Mn |
| Dec 31, 2024 | 129.77 Mn |
| Dec 31, 2024 | 129.77 Mn |
| Sep 30, 2024 | 121.74 Mn |
| Sep 30, 2024 | 121.74 Mn |
| Jun 30, 2024 | -78.04 Mn |
| Jun 30, 2024 | -78.04 Mn |
| Mar 31, 2024 | 105.47 Mn |
| Mar 31, 2024 | 105.47 Mn |
| Dec 31, 2023 | 116.22 Mn |
| Dec 31, 2023 | 116.22 Mn |